Overview

• Organic sales rose 3.9% in the second quarter as a 5% jump in volumes offset a 1.2% decline in prices.
• Adjusted earnings per share reached $1.92, surpassing the $1.67 analysts had expected.
• The company lifted its full-year 2025 adjusted EPS growth target to a low- to mid-single-digit rate from a prior flat-to-positive outlook.
• Full-year tariff-related cost projections were cut to about $170 million following the reduction of U.S.-China levies.
• A $3.4 billion joint venture with Suzano is advancing to streamline the international tissue business and improve margins.